Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients

BACKGROUND: Lactate dehydrogenase (LDH) represents a predictive factor in colorectal cancer patients treated with the angiogenesis inhibitor PTK/ZK. We explored the role of pre-treatment LDH serum levels in colorectal cancer patients receiving first-line bevacizumab. METHODS: Metastatic colorectal c...

Descripción completa

Detalles Bibliográficos
Autores principales: Scartozzi, M, Giampieri, R, Maccaroni, E, Del Prete, M, Faloppi, L, Bianconi, M, Galizia, E, Loretelli, C, Belvederesi, L, Bittoni, A, Cascinu, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305976/
https://www.ncbi.nlm.nih.gov/pubmed/22315053
http://dx.doi.org/10.1038/bjc.2012.17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305976/
https://www.ncbi.nlm.nih.gov/pubmed/22315053
http://dx.doi.org/10.1038/bjc.2012.17

Ejemplares similares